# XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

> **NCT05494060** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Carcinoma
- Gastrointestinal Diseases
- Stomach Cancer
- Gastroesophageal-junction Cancer
- Digestive System Diseases
- Gastric Cancer
- Gastrointestinal Neoplasms

## Interventions

- **DRUG:** Anlotinib hydrochloride capsule
- **DRUG:** Penpulimab Injection
- **DRUG:** XELOX

## Key facts

- **NCT ID:** NCT05494060
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-16
- **Primary completion:** 2024-12
- **Final completion:** 2027-02
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05494060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05494060, "XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05494060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*